Cerdelga (Eliglustat Tartrate) Patent Expiration, LOE Window & CMS Spending

Cerdelga (Eliglustat Tartrate) by Sanofi: FDA Orange Book core substance LOE 2030-11-24 (last listed 2038-12-13), 2 AB generics, $64.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN205494 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-11-24
Last Listed Patent or Exclusivity Date2038-12-13
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$64.2M
2024 Medicare Part D Spend$42.1M
2024 Medicaid Spend$22.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.